News
PURPOSEPhase III studies of intravenous amivantamab demonstrated efficacy across epidermal growth factor receptor (EGFR)–mutated advanced non–small cell lung cancer (NSCLC). A subcutaneous formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback